#ACC17 – Highlights from the American College of Cardiology’s 66th Annual Scientific Session
1 – #ACC17 – PCI, Drugs Equally Beneficial for Treating Fully Blocked Arteries: Study shows percutaneous coronary intervention is not needed in all cases – Latest in Cardiology, American College of Cardiology (free)
See also: First Clinical Trial of CTO Procedures Fails to Deliver – Medscape (free registration required)
– Among patients with at least one coronary chronic total occlusion (CTO), percutaneous coronary intervention (PCI) added to optimal medical therapy did not improve outcomes.
Editorial: PCSK9 Inhibition to Reduce Cardiovascular Events (free)
See also: Ten Quick Thoughts on FOURIER – Medscape (free registration required) AND Pricey New Cholesterol Drug’s Effect On Heart Disease Is More Modest Than Hoped – NPR Health News (free)
“Evolocumab did not reduce cardiovascular or death from any cause. There was not even a trend for improvement” (see Medscape commentary above)
Editorial: Complete Revascularization in ST-Elevation Myocardial Infarction? (free)
“The advantage in Compare-Acute was mostly due to fewer repeat revascularizations; larger trials are needed to assess hard outcomes.” (TCTMD commentary above).
“Mortality and stroke at 2 years were similar with surgery and transcatheter aortic-valve replacement, but different adverse events were associated with each procedure” (from commentary above)
“Effect persists for years, underscoring the need for mental health screening and treatment”.
7 – #ACC17 – Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study – The Lancet (link to abstract – $ required for full-text)
See also: ‘Healthiest hearts in the world’ found – BBC News (free) AND Indigenous Bolivians Have Some of the Healthiest Hearts – New York Times (free access to 10 articles per month)
See also: Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE – TCTMD (free) AND ACC: Even Very Low Dose Rivaroxaban Prevents Recurrent VTE – MedPage Today (free registration required) AND Low-Dose Rivaroxaban vs. Aspirin Reduces Recurrent VTE in EINSTEIN CHOICE – Latest in Cardiology, American College of Cardiology (free)
“The number needed to treat to prevent one VTE was 30 with the 10 mg dose of rivaroxaban and 33 with the 20 mg dose of rivaroxaban” (see Latest in Cardiology commentary above).
See also: Lifestyle intervention leads to 10-point drop in systolic blood pressure – ScienceDaily (free) AND Internet-Based Lifestyle Counseling Reduces Hypertension, Improves CVD Risk – CardiologyAdvisor (free) AND ACC: Online Videos Help HTN Adherence: Blood pressure, Framingham risk improved in small trial – MedPage Today (free registration required)